News

Interim FDG-PET 'Not Justified' in Diffuse Large B-Cell Lymphoma

Publish date: July 13, 2011

 

FROM THE ANNUAL CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION

Dr. Cox and Dr. Pettitt stated that they had no relevant financial disclosures.

Pages

Recommended Reading

Rare Lymphoma Reports Continue in Young Patients on TNF Blockers
MDedge Hematology and Oncology
Low-Dose Irradiation Allays 93% of Gastric MALT Lymphomas at 10 Years
MDedge Hematology and Oncology
Transplant in First Remission Holds Off Progression in Non-Hodgkin's Lymphoma
MDedge Hematology and Oncology
Transplant in First Remission Holds Off Progression in Non-Hodgkin's Lymphoma
MDedge Hematology and Oncology
Chemo Length May Not Affect Survival in Some B-cell Lymphomas
MDedge Hematology and Oncology
Rituximab Maintenance Called "New Standard" for Mantle Cell Lymphoma
MDedge Hematology and Oncology
Rituximab Maintenance Called "New Standard" for Mantle Cell Lymphoma
MDedge Hematology and Oncology
Studies Mixed on Second Cancers After Lenalidomide
MDedge Hematology and Oncology
Treat HIV-Related Hodgkin's Like Non-HIV Disease
MDedge Hematology and Oncology
Brentuximab Benefits Hodgkin's Patients Ineligible for Transplant
MDedge Hematology and Oncology